Source comparison
Subcutaneous vs Intravenous Administration Kinetics
Route of administration alters hexarelin's absorption profile but not its elimination half-life once systemic circulation is reached. Intravenous bolus delivers immediate peak plasma concentration (Cmax) within 5–10 minutes, followed by rapid two-phase elimina
This comparison does not assign a generated winner or score.
- Route of administration alters hexarelin's absorption profile but not its elimination half-life once systemic circulation is reached. Intravenous bolus delivers immediate peak plasma concentration (Cmax) within 5–10 minutes, followed by rapid two-phase elimination. An initial distribution phase (alpha half-life ~15 minutes) and a terminal elimination phase (beta half-life 70–80 minutes). Subcutaneous injection delays Cmax to approximately 20–30 minutes post-administration as the peptide diffuses from the injection depot into capillaries, but the terminal elimination half-life remains identical at 70–80 minutes.
- The GH response curve, however, shifts slightly between routes. IV administration produces a sharper, higher-amplitude GH peak (often 15–25% higher than subcutaneous), but the overall area under the curve (AUC) for GH secretion across the 6-hour observation window differs by less than 10%. Subcutaneous delivery generates a more physiological, sustained GH pulse that researchers often prefer when mimicking endogenous pulsatile patterns.
- Intramuscular administration. Occasionally used in veterinary research but rare in human protocols. Produces kinetics intermediate between IV and subcutaneous routes: Cmax at 15–20 minutes, terminal half-life unchanged. Regardless of route, the peptide's effect on GH pulsatility persists 4–6 hours, reinforcing that receptor pharmacodynamics govern functional duration more than absorption speed.
- Here's what we've learned through protocol optimisation work: subcutaneous remains the preferred route for multi-week studies because it reduces peak-trough variability, lowers the risk of acute receptor saturation, and better sustains physiological GH pulsatility. IV boluses serve research questions focused on peak GH capacity testing or receptor reserve assessment. Not chronic administration studies.